Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

Review
.2011 Jan;24(1):193-209.
doi: 10.1128/CMR.00044-10.

Progress and problems in understanding and managing primary Epstein-Barr virus infections

Affiliations
Review

Progress and problems in understanding and managing primary Epstein-Barr virus infections

Oludare A Odumade et al. Clin Microbiol Rev.2011 Jan.

Abstract

Epstein-Barr virus (EBV) is a gammaherpesvirus that infects a large fraction of the human population. Primary infection is often asymptomatic but results in lifelong infection, which is kept in check by the host immune system. In some cases, primary infection can result in infectious mononucleosis. Furthermore, when host-virus balance is not achieved, the virus can drive potentially lethal lymphoproliferation and lymphomagenesis. In this review, we describe the biology of EBV and the host immune response. We review the diagnosis of EBV infection and discuss the characteristics and pathogenesis of infectious mononucleosis. These topics are approached in the context of developing therapeutic and preventative strategies.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
EBV infection in healthy carriers. Primary EBV infection begins in the oral cavity. EBV uses different glycoproteins to infect epithelial cells and naïve B cells. Viral entry results in transport of the EBV genome into the B-cell nucleus, where replication by cellular and viral DNA polymerases begins. EBV gene products activate the B-cell growth program, resulting in the proliferation of blasting B cells. Priming of naïve T cells by antigen-presenting cells occurs in parallel. Normally, these blasting B cells are destroyed by cytotoxic T lymphocytes. Once in the circulation, previously activated memory B cells may continue to undergo lytic replication or, if EBV shuts down most of its protein-encoding genes, latency occurs. At a later time, as cells recirculate between the oral and peripheral compartments, resting B cells may be activated, resulting in viral reactivation and shedding.
FIG. 2.
FIG. 2.
Kinetics of EBV-specific antibodies and viral load in infectious mononucleosis. The graph shows the evolution of EBV replication and EBV-specific antibodies measured by EIA during primary infection. At presentation, EBV may not be detected in the blood but is usually found in large quantities in the oral cavity. Virus is cleared from the blood much more rapidly than from the oral compartment. Oral viral shedding can persist for months and recurs intermittently for years in most healthy adults. At the onset of illness, most patients have IgM antibodies to EBV VCA; these decline between 2 and 6 months after infection. VCA IgG antibodies may be detected as early as during the first 2 weeks of illness. Essentially 100% of patients have detectable VCA IgG antibodies during convalescence, and these persist for life. EBNA1 IgG antibodies do not develop until 3 to 6 months after infection but then persist for life.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alfieri, C., F. Ghibu, and J. H. Joncas. 1984. Lytic, nontransforming Epstein-Barr virus (EBV) from a patient with chronic active EBV infection. Can. Med. Assoc. J. 131:1249-1252. - PMC - PubMed
    1. Alfieri, C., et al. 1996. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 87:812-817. - PubMed
    1. Ambinder, R. F., and L. Lin. 2005. Mononucleosis in the laboratory. J. Infect. Dis. 192:1503-1504. - PubMed
    1. Amon, W., and P. J. Farrell. 2005. Reactivation of Epstein-Barr virus from latency. Rev. Med. Virol. 15:149-156. - PubMed
    1. Andersson, J., et al. 1986. Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study. J. Infect. Dis. 153:283-290. - PubMed

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp